Veritope Technology Platform
Abreos Biosciences has developed a platform to identify proprietary peptide-based ligands (Veritopes) that can measure and purify biologic molecules. Veritopes are selective, scale-able, and amendable to use in multiple formats including sandwich ELISA for drug level detection and resin based chromatography for biopurification.
Conventional methods for detecting biologic drugs use either purified or recombinant protein targets or anti-idiotypic (anti-id) antibodies. These methods are time-consuming, often unstable, highly variable, and very expensive.
Veritopes are robust, cost-effective, highly specific, and easily adapted to different assay methods or purification formats.
How Veritopes Work
The Veritope platform is a proprietary reagent platform based on peptide mimetopes that detect a given biologic or biosimilar drug by mimicking the natural target, including cell membrane bound proteins (US patent 9,250,233). Veritopes specifically detect the target biologic drug in human samples such as serum and plasma and can be implemented in lab-based assays such as ELISA or lateral flow assay (LFA) for point-of-care (POC) applications.
*For Research Use Only. Not for use in diagnostic procedures.
Measurement: Precision Dosing. Precision Care.
Biologic drugs have revolutionized treatment options for patients with cancer and chronic autoimmune disorders. However, amidst this positive climate, a growing and substantial problem exists in this era of personalized medicine: response to biologics varies by individual patient. The same dose of a drug can result in different amounts of effective drug circulating the blood stream, leading to unpredictable results.
One dose does not necessarily fit all - response varies and requires monitoring. Our assays based on robust mimetope peptides, termed Veritopes, allow researchers and physicians to quantitate the amount of active biologic drug circulating in the blood, which is informative for establishing appropriate dosing interval. Moving forward, therapeutic drug monitoring will help maximize the efficacy of biologic drugs.
Abreos has partnered with a CLIA-certified, CAP-accredited laboratory to offer therapeutic drug monitoring tests for patients, physicians, and researchers.
Biologic drugs are produced in mammalian cell culture systems, requiring downstream purification through multi-step processes. The most expensive, harsh, and limiting of those steps is affinity capture by Protein A, a market that is projected to reach $500M by 2020. Abreos will leverage a novel form of weak affinity chromatography based on the use of mimetope peptides specific for a given biologic drug. With this technology, a broader array of biologic therapies will be manufacturable at reasonable costs to benefit patients around the globe.
Publications, Posters, & Presentations